TABLE 3.
Univariable Cox regression analyses for the mortality and ARDS in COVID‐19 patients with hypertension
| Mortality(n = 22) | ARDS (n = 64) | |||
|---|---|---|---|---|
| Variable | HR (95%CI) | p‐value | HR (95%CI) | p‐value |
| Age | 1.05 (1.01–1.10) | .018 | 1.05 (1.02–1.07) | <.001 |
| Sex | 2.07 (0.85–5.09) | .111 | 1.22 (0.75–2.00) | .429 |
| Smoking history | 0.67 (0.09–4.99) | .696 | 0.68 (0.21–2.19) | .522 |
| Diabetes | 0.60 (0.20–1.77) | .351 | 0.79 (0.44–1.43) | .439 |
| Coronary heart disease | 3.29 (1.29–8.42) | .013 | 1.38 (0.68–2.79) | .373 |
| COPD | 4.06 (1.37–12.0) | .011 | 4.27 (2.17–8.41) | <.001 |
| Tumor | 2.23 (0.30–16.64) | .434 | 3.29 (1.19–9.11) | .022 |
| ACEI/ARB | 0.41 (0.05–3.05) | .383 | 0.87 (0.38–2.02) | .748 |
| β blocker | 0.45 (0.10–1.93) | .281 | 1.77 (1.00–3.13) | .049 |
| Calcium channel blocker | 0.39 (0.16–0.92) | .032 | 1.00 (0.61–1.65) | .988 |
| Diuretic | 1.68 (0.39–7.21) | .482 | 4.19 (2.23–7.87) | <.001 |
| Antiviral therapy | 2.27 (0.97–5.34) | .059 | 1.25 (0.76–2.06) | .372 |
| Glucocorticoid | 4.65 (1.98–10.91) | <.001 | 5.29 (3.21–8.72) | <.001 |
| Leukocyte count < 4×10 9 /L | 1.14 (0.15–8.50) | .896 | 0.05 (0.00–13.05) | .287 |
| D‐dimer > 0.55 mg/L | 8.79 (2.03–38.07) | .004 | 14.69 (5.31–40.63) | <.001 |
| AST > 40 u/L | 16.73 (7.01–39.93) | <.001 | 4.62 (2.69–7.91) | <.001 |
| Creatinine > 133 μmol/L | 9.76 (3.78–25.19) | <.001 | 4.32 (2.13–8.76) | <.001 |
| LDH > 250 u/L | 42.06 (9.83–180.01) | <.001 | 12.20 (7.11–20.91) | <.001 |
| hs‐TnI > 0.04 ng/ml | 17.73 (6.84–45.95) | <.001 | 8.37 (94.64–15.09) | <.001 |
| BNP > 100 pg/ml | 6.06 (2.46–14.92) | <.001 | 4.81 (2.76–8.38) | <.001 |
| hs‐CRP > 4 mg/L | 76.81 (2.26–2613.39) | .016 | 26.25 (8.23–83.72) | <.001 |
| PCT > 0.05 ng/ml | 17.44 (2.31–131.57) | .006 | 6.61 (3.11–14.08) | <.001 |
| mean SBP | 1.00 (0.96–1.04) | .950 | 0.99 (0.97–1.02) | .567 |
| mean DBP | 0.88 (0.83–0.94) | <.001 | 0.90 (0.87–0.94) | <.001 |
| Assessments of BPV | ||||
| SD SBP | 1.29 (1.20–1.40) | <.001 | 1.19 (1.13–1.25) | <.001 |
| CV SBP | 1.38 (1.27–1.51) | <.001 | 1.27 (1.19–1.35) | <.001 |
| VIM SBP | 1.28 (1.20–1.37) | <.001 | 1.20 (1.14–1.25) | <.001 |
| SD DBP | 1.34 (1.21–1.48) | <.001 | 1.18 (1.10–1.27) | <.001 |
| CV DBP | 1.26 (1.18–1.34) | <.001 | 1.16 (1.11–1.22) | <.001 |
| VIM DBP | 1.35 (1.23–1.48) | <.001 | 1.20 (1.13–1.29) | <.001 |
ARDS, acute respiratory distress syndrome; HR, hazard ratio; CI, confidence interval; COPD, Chronic obstructive lung disease; ACEI, angiotensin‐converting enzyme inhibitor; ARB, angiotensin receptor blocker; AST, aspartate aminotransferase; hs‐TnI, high‐sensitive cardiac troponin I; BNP, B‐type natriuretic peptide; hs‐CRP, high‐sensitive C‐reactive protein; SBP, systolic blood pressure; DBP, diastolic blood pressure; PCT, procalcitonin.